- Cite This Article as
- Corresponding Author
The molecular classification for breast carcinomas has been used in clinical studies with a simple surrogate panel of immunohistochemistry (IHC) markers. The objective of this current project was to study the molecular classification of commonly used breast cancer by IHC analysis. Fifty breast cancer samples were collected , fixed in formalin and made into paraffin blocks. IHC analyses were performed on each block with antibodies to estrogen receptor (ER), progesterone receptor (PR) and HER2. Among the 50 samples, Estrogen positive receptors were in 48% (24/50) of the cases, progesterone positive receptors in 46 % (23/50) of the cases and HER2 was 7 of 50 malignant cases (14%) were positive for her-2/neu expression while 74 % for score 0 and score 1 which consider as her-2/neu negative. Luminal A subtype:54% (27/50) ; 4%(2/50) cases that refer to Luminal B subtype ; 10% (5/50) Cases which were referred to HER2 over-expression subtype and 32%(16/50) cases to basal subtype. Since each subtype defined by this IHC-based molecular classification does show a distinct clinical outcome, attention should be paid when choosing this markers for any study.
[Iman H.Mohsen AL-Bedairy, Hasan F. AL.Azzawie, Abdul Kareem AL-Kazaz ,Mohammed Ghanim (2014); Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in Iraqi breast carcinoma women Int. J. of Adv. Res. 2 (6). 0] (ISSN 2320-5407). www.journalijar.com
Share this article
This work is licensed under a Creative Commons Attribution 4.0 International License.